What You Need To Know About La Jolla Pharmaceutical Company's (NASDAQ:LJPC) Investor Composition
The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Insiders...
Simply Wall St. · 06/10 08:57
46 Stocks Moving In Thursday's Mid-Day Session
Gainers GTT Communications, Inc. (NYSE: GTT) shares jumped 66% to $4.16 on abnormally-high volume. The company’s stock also jumped over 57% on Wednesday.
Benzinga · 06/03 16:09
Thinking about buying stock in La Jolla Pharmaceutical, The GEO Group, Abeona Therapeutics, Sellas Life Sciences, or Naked Brand?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LJPC, GEO, ABEO, SLS, and NAKD.
PR Newswire - PRF · 06/03 13:31
BB, WKHS, SNDL and GEO among notable premarket gainers
Jiuzi Holdings (JZXN) +49%.GTT Communications (GTT) +28%.Community Bankers Trust Corporation ESXB +26% on merger agreement with United Bankshares.Tellurian TELL +26% on 10-year LNG sales deal with Vitol.Workhorse Group (WKHS) +16%.Auris Medical Holding (EA...
Seekingalpha · 06/03 12:23
Significant Insider purchase of La Jolla Pharmaceutical Co (LJPC) Shares Extends the Buying Trend of Last Quarter
MT Newswires · 06/02 22:24
Insider Trends: Insider Buying Added to with Purchase of La Jolla Pharmaceutical Co Shares
MT Newswires · 06/01 18:55
Insiders at La Jolla Pharmaceutical Co (LJPC) Make Significant purchases of Stock
MT Newswires · 05/27 22:21
60 Biggest Movers From Yesterday
Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday.
Benzinga · 05/27 09:11
Insider Trends: Insider Purchase Adds to La Jolla Pharmaceutical Co Positive Trend
MT Newswires · 05/26 17:06
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC) · 05/18 10:22
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 05/14 11:59
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates · 05/07 14:05
La Jolla Pharmaceutical shares rise on Q1 topline beat
La Jolla Pharmaceutical (LJPC) shares rise more than 10% during premarket trading after the company posted first-quarter revenue that beat Wall Street estimates.The company's total revenue increased 349.8% to $34.1M, beating analysts' estimate
Seekingalpha · 05/07 13:22
La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue
La Jolla Pharmaceutical (LJPC): Q1 GAAP EPS of $0.42 misses by $0.14.Revenue of $34.14M (+349.8% Y/Y) beats by $0.99M.As of March 31, 2021 and December 31, 2020, La Jolla had
Seekingalpha · 05/07 12:54
BRIEF-La Jolla Pharmaceutical Co Announces Financial Results For Q1 · 05/07 12:53
La Jolla Pharmaceutical Q1 EPS $0.42 Up From $(0.32) YoY, Sales $34.14M Up From $7.59M YoY
La Jolla Pharmaceutical (NASDAQ:LJPC) reported quarterly earnings of $0.42 per share. This is a 231.25 percent increase over losses of $(0.32) per share from the same period last year. The company reported $34.14
Benzinga · 05/07 12:45
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three ...
BusinessWire · 05/07 12:45
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 05/07 12:33
-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Reports Q1 Revenue $34.1M
MT Newswires · 05/07 08:57
La Jolla Pharmaceutical Company (NASDAQ:LJPC) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Simply Wall St. · 03/11 08:12
Webull provides a variety of real-time LJPC stock news. You can receive the latest news about La Jolla Pharm through multiple platforms. This information may help you make smarter investment decisions.
About LJPC
La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of intra-abdominal infections in patients 18 years of age and older. The LJPC-0118 (I.V. artesunate) is the Company’s investigational product for the treatment of malaria. The LJPC-401 (synthetic human hepcidin) is the Company’s investigational product for the treatment of conditions characterized by iron overload.